The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz EMERGE 402 study.

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.

According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

The FDA approved selumetinib as treatment for pediatric neurofibromatosis type 1, expanding options for young patients with inoperable plexiform neurofibromas.

Rates of grade 3 or 4 AEs with durvalumab were similar across subgroups, with serious AEs more frequent in patients 70 years or older with ES-SCLC.

The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy.

In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.

When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.